FHTX combines fast reported revenue growth and a string of earnings beats with a large stated discount to its analyst target, but its $356M market cap falls below the engine's investable-universe minimum and momentum has failed to confirm.
Thesis pillars
- Market Cap Below Investable Threshold↓Deteriorating
- Strong Revenue Growth Leader→Stable
- Consistent Earnings Beats→Stable
- +2 more pillars — see the Why tab for full reasoning
Foghorn Therapeutics Inc. (FHTX) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $4.45, but acceptable to hold if already in. Reasons: Concentration risk — Pipeline: FHD-909; Market cap $262M below $400M minimum.
Foghorn Therapeutics Inc. is a clinical-stage precision therapeutics company developing small-molecule medicines that target the chromatin regulatory system, using its proprietary Gene Traffic Control platform, primarily in oncology. Its lead candidate, FHD-909, a SMARCA2... Read more
Hold if already holding. Not a fresh buy at $4.45, but acceptable to hold if already in. Reasons: Concentration risk — Pipeline: FHD-909; Market cap $262M below $400M minimum. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $262M below $400M minimum. Not in investable universe. Score 5.7/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 52d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
About Foghorn Therapeutics Inc.
About Foghorn Therapeutics Inc.
Foghorn Therapeutics is advancing more than seven chromatin-regulatory-system programs, with just one, FHD-909 — a SMARCA2 inhibitor Lilly selected for clinical development in February 2024 — in Phase 1 testing after dosing its first patient in October 2024. The company employed 106 people as of December 31, 2025, has no product revenue, and carries a $632.5 million accumulated deficit funded primarily through its Lilly collaboration, prior stock offerings, and its IPO.
Foghorn generates no product sales; its economics run through collaboration payments and equity investment from Eli Lilly, which entered a strategic collaboration in December 2021 covering a U.S. co-development and co-commercialization agreement for the SMARCA2 oncology program (FHD-909) plus an undisclosed second oncology target and three additional discovery programs. The company's Gene Traffic Control platform screens for enzyme inhibitors, protein degraders, and transcription-factor disruptors against named targets including SMARCA2, CBP, EP300, and ARID1B, and Foghorn has disclosed plans to file up to four Investigational New Drug applications over the next two years, spanning oncology and, longer term, other disease areas such as immunology. Early manufacturing of clinical supplies runs through third-party arrangements rather than in-house production, consistent with a discovery-stage biotech that has not yet built commercial infrastructure.
Show full overview
FHD-909 functions as Foghorn's sole clinical-stage bet: every other program in the pipeline remains preclinical, and the filing states plainly that the company has one product candidate, FHD-909, partnered with Lilly, in Phase 1 development. Because Lilly leads and funds that trial under the 2021 collaboration agreement, Foghorn's near-term catalysts depend on a partner's execution and prioritization rather than its own clinical operations — a structure that also means the roughly $632.5 million the company has spent to date has not yet produced a single late-stage or commercial asset it fully controls.
See also: Healthcare · Biotechnology
From Foghorn Therapeutics Inc.'s most recent 10-K filing, extracted August 30, 2026.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineFHD-90910-K Item 1A: 'We have one product candidate, FHD-909, which is partnered with Lilly, in Phase 1 clinical development; our other product candidates are in preclinical development'
- MEDIUMcounterpartyLilly10-K Item 1A: 'We have financed our operations primarily through our strategic collaboration with Lilly and Lilly’s concurrent investment in our equity'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Volatile — 9.1% daily ATR makes tight stops impractical. Position-size conservatively.static
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $4.45, but acceptable to hold if already in. Reasons: Concentration risk — Pipeline: FHD-909; Market cap $262M below $400M minimum. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $262M below $400M minimum. Not in investable universe. Target $9.96 (+123.8%), stop $4.24 (−5.0%), A.R:R 8.3:1. Score 5.7/10, moderate confidence.
Take-profit target: $9.96 (+125.3% upside). Target $9.96 (+123.8%), stop $4.24 (−5.0%), A.R:R 8.3:1. Stop-loss: $4.24.
Concentration risk — Pipeline: FHD-909; Market cap $262M below $400M minimum.
Foghorn Therapeutics Inc. trades at a P/E of N/A (forward -4.1). TrendMatrix value score: 7.6/10. Verdict: Hold.
16 analysts cover FHTX with a consensus score of 4.4/5. Average price target: $11.
What does Foghorn Therapeutics Inc. do?Foghorn Therapeutics Inc. is a clinical-stage precision therapeutics company developing small-molecule medicines that...
Foghorn Therapeutics Inc. is a clinical-stage precision therapeutics company developing small-molecule medicines that target the chromatin regulatory system, using its proprietary Gene Traffic Control platform, primarily in oncology. Its lead candidate, FHD-909, a SMARCA2 inhibitor partnered with Eli Lilly, entered Phase 1 trials in October 2024; the company has no approved products or product revenue and an accumulated deficit of $632.5 million as of December 31, 2025.